Fundraising Fox
/Companies
Sign in

scPharmaceuticals

Acquired

Lexington, US · Founded 2014 · Delaware corporation · 40 employees on LinkedIn · 1 known investors

Find your way into scPharmaceuticals

Sign up to find every way you can get introduced to scPharmaceuticals

  • Your email: who you already know at scPharmaceuticals, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the scPharmaceuticals team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Acquired by MannKind Corporation October 2025 · $360M (Up to $6.35 per share (approx. $303M equity value at closing, up to $360M total deal value)) · source ↗

scPharmaceuticals was a commercial-stage biopharmaceutical company that developed FUROSCIX, an FDA-approved subcutaneous formulation of the diuretic furosemide for treating fluid overload in heart failure and kidney disease patients.

Biotech

Founders & leadership

PM
Pieter MuntendamNamed on SEC filing

Board

MK
Mette Kirstine AggerBoard director
KPKush Parmar
Kush ParmarBoard of Directors2014–2018Managing Partner at 5AM Ventures
DC
Dorothy ColemanBoard director
LS
Leonard SchaefferBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$71.8M disclosed across 5 rounds · 2014–2016

▶$47MraisedJan 2017 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorothy ColemanDirector
  • Abraham CeesayExecutive Officer
  • Troy IgnelziExecutive Officer
  • Kush ParmarDirector
  • Leonard SchaefferDirector
  • Mette AggerDirector
  • Pieter MuntendamExecutive Officer, Director
  • Jack KhattarDirector
  • Abhay GandhiDirector
  • Jonathan SilversteinDirector
Offering amount
$47M
Amount sold
$47M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.2MraisedSep 2016 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonard SchaefferDirector
  • Abraham CeesayExecutive Officer
  • Pieter MuntendamExecutive Officer, Director
  • Kush ParmarDirector
  • Jack KhattarDirector
  • Troy IgnelziExecutive Officer
  • Mette AggerDirector
  • Dorothy ColemanDirector
Offering amount
$8.2M
Amount sold
$8.2M
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedSep 2016 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter MuntendamExecutive Officer, Director
  • Mette AggerDirector
  • Jack KhattarDirector
  • Dorothy ColemanDirector
  • Kush ParmarDirector
  • Leonard SchaefferDirector
  • Abraham CeesayExecutive Officer
  • Troy IgnelziExecutive Officer
Offering amount
$10M
Amount sold
$4M
Proceeds to insiders
$468.6K
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6MraisedFeb 2016 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter MuntendamExecutive Officer, Director
  • Mette Kirstine AggerDirector
  • Dorothy ColemanDirector
  • Leonard SchaefferDirector
  • Kush ParmarDirector
Offering amount
$7.5M
Amount sold
$3.6M
Proceeds to insiders
$171.8K
First sale
Jan 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.1MraisedApr 2014 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter MuntendamExecutive Officer, Director
  • Mette Kirstine AggerDirector
  • Kush ParmarDirector
Offering amount
$17.1M
Amount sold
$9.1M
First sale
Mar 2014
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does scPharmaceuticals do?
scPharmaceuticals was a commercial-stage biopharmaceutical company that developed FUROSCIX, an FDA-approved subcutaneous formulation of the diuretic furosemide for treating fluid overload in heart failure and kidney disease patients.
Who are scPharmaceuticals's investors?
scPharmaceuticals's investors include 5AM Ventures.
How much funding has scPharmaceuticals raised?
scPharmaceuticals has disclosed $71.8M raised across 5 rounds.
Where is scPharmaceuticals headquartered?
scPharmaceuticals is headquartered in Lexington, US.